Replimune — Fiscal Second Quarter 2027 Earnings Summary

Replimune Group, Inc. reported fiscal second quarter 2027 financial results, announcing a net loss of $57.1 million for the three months ended September 30, 2026. The company's cash and cash equivalents increased to $307.8 million as of September 30, 2026, driven by proceeds from a common stock offering and debt drawdowns. TUDRIQEV, an oncolytic viral therapy indicated for advanced melanoma, became commercially available in the United States in early October 2026 and has been prescribed by more than 15 institutions. Research and development expenses decreased to $34.4 million for the quarter, while the company confirmed that its current cash position supports operations for over twelve months.